type of report	**Current report**
number	10/2013
company	PHARMENA

Commencing clinical trials of 1-MNA medicinal product

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and current report no. 9/2013 of 22nd February 2013 (which concerned obtaining permission for conducting bioavailability testing of 1-MNA medicinal product), the Management Board of Pharmena S.A. informs that it is scheduled to commence bioavailability testing of an innovative anti-atherosclerotic medicinal product based on 1-MNA active substance (working name of the product – TRIA-662), managed by Cortria Corporation (USA), on 1st March 2013. The trials will be conducted by a Canadian clinic Bio Pharma Services Inc. It is planned to perform a bioavailability testing (randomised, double-blind) on a group of 20 patients. It will focus on two testing groups: 1-MNA vs. niacin (active substance used in currently sold anti-atherosclerotic medicines) in 1000 mg dose. The anticipated duration of the trials is approximately 2 months.

Bioavailability testing determines the time and levels of absorption of medicinal substance into the general circulation of human organism after single administration. Bioavailability testing is indispensible for carrying out phase II of clinical trials ("Proof of Concept") of anti-atherosclerotic medicinal product 1-MNA, in order to confirm its efficacy and absence of adverse side effects with increased doses. Bioavailability testing will be financed from funds obtained from the issue of series C shares.

Bio Pharma Services Inc. is a research centre specializing in bioavailability and bioequivalence testing commissioned by pharmaceutical companies from, among others, USA, Canada and Europe. For more information, please visit www.biopharmaservices.ca.

The information is made public due to the fact that the bioavailability testing of 1-MNA anti-atherosclerotic medicinal product is necessary to carry out phase II of clinical trials of that product. Potential revenue after commercialisation of the anti-atherosclerotic medicinal product may prove to be very beneficial for the financial and economic situation of the Issuer.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:
- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board